Tectonic Therapeutic Inc/$TECX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Tectonic Therapeutic Inc
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
- Ticker
- $TECX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 60
- Headquarters
- Watertown, United States
- Website
- tectonictx.com
TECX Metrics
BasicAdvanced
$386M
-
-$4.56
0.22
-
Price and volume
Market cap
$386M
Beta
0.22
52-week high
$39.53
52-week low
$15.52
Average daily volume
222K
Financial strength
Current ratio
22.287
Quick ratio
21.899
Long term debt to equity
0.013
Total debt to equity
0.02
Interest coverage (TTM)
-2,373.13%
Profitability
EBITDA (TTM)
-93.661
Effective tax rate (TTM)
-0.39%
Management effectiveness
Return on assets (TTM)
-22.29%
Return on equity (TTM)
-33.80%
Valuation
Price to book
1.7
Price to tangible book (TTM)
1.7
Price to free cash flow (TTM)
-5.133
Free cash flow yield (TTM)
-19.48%
Free cash flow per share (TTM)
-3.853
Growth
Earnings per share change (TTM)
13.29%
What the Analysts think about TECX
Analyst ratings (Buy, Hold, Sell) for Tectonic Therapeutic Inc stock.
Analyst projections of the future price of Tectonic Therapeutic Inc stock.
Bulls say / Bears say
TX2100’s Phase 1a study reported favourable safety, tolerability and pharmacokinetic results, and the FDA granted Fast Track status and cleared a Phase 1b trial in HHT. This advances a second programme towards patient testing for a condition with no approved therapies. (SEC)
Tectonic completed enrolment in the 191-patient TX45 APEX Phase 2 trial, with 72% of participants in its targeted, more severe disease subgroup. After reviewing unblinded data covering about 80% of expected patient exposure, the independent committee recommended continuing the study without changes. (SEC)
The company reported $227.1 million in cash at the end of June and expects its funds to last into the first quarter of 2029. Management says that should cover the TX45 Phase 2 readouts and significant TX2100 milestones, easing near-term financing pressure. (GlobeNewswire)
TX45 still has to show that improved pulmonary blood-flow measures lead to benefits patients can feel. UBS views a meaningful improvement in six-minute walk distance as a tougher hurdle, with roughly even odds in Phase 2. (StreetInsider)
The relaxin approach carries a safety overhang: earlier work in the drug class was halted after excess heart-failure hospitalisations and congestion. Tectonic still needs to show TX45 can avoid that risk during ongoing treatment. (Investing.com)
TX2100’s initial study was conducted in healthy volunteers, so it has not yet established safety or benefit in people with HHT. Its potential still depends on forthcoming patient trials. (Cure HHT)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.
TECX Financial Performance
Revenues and expenses
TECX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing TECX
Fund name | Fund size | $TECX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.